Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion

We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled recept...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmacology Vol. 75; no. 1; pp. 134 - 142
Main Authors Tradtrantip, Lukmanee, Yangthara, Buranee, Padmawar, Prashant, Morrison, Christopher, Verkman, A.S.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2009
American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text

Cover

Loading…
Abstract We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl- current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
AbstractList We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC(50) of <5 microM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl(-) current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC 50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl - current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC 50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl - current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the 2-(acylamino)-3-thiophenecarboxylates, strongly suppressed cAMP and cGMP in multiple cell lines in response to different agonists acting on G-protein-coupled receptors, adenylyl cyclase, and guanylyl cyclase. The best compounds from structure-activity analysis of 124 analogs, including several synthesized chiral analogs, had and IC50 of <5 μM for suppression of agonist-induced cAMP and cGMP elevation. Measurements of cAMP, cGMP, and downstream signaling in response to various activators/inhibitors suggested that the 2-(acylamino)-3-thiophenecarboxylates function as nonselective phosphodiesterase activators, although it was not determined whether their action on phosphodiesterases is direct or indirect. The 2-(acylamino)-3-thiophenecarboxylates suppressed CFTR-mediated Cl- current in T84 colonic cells in response to cholera and Escherichia coli (STa) toxins, and prevented intestinal fluid accumulation in a closed-loop mouse model of secretory diarrhea. They also prevented cyst growth in an in vitro renal epithelial cell model of polycystic kidney disease. The 2-(acylamino)-3-thiophenecarboxylates represent the first small-molecule cyclic nucleotide suppressors, whose potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and growth inhibition of cAMP-dependent tumors.
Author Padmawar, Prashant
Tradtrantip, Lukmanee
Yangthara, Buranee
Verkman, A.S.
Morrison, Christopher
AuthorAffiliation Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California, San Francisco, California
AuthorAffiliation_xml – name: Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California, San Francisco, California
Author_xml – sequence: 1
  givenname: Lukmanee
  surname: Tradtrantip
  fullname: Tradtrantip, Lukmanee
– sequence: 2
  givenname: Buranee
  surname: Yangthara
  fullname: Yangthara, Buranee
– sequence: 3
  givenname: Prashant
  surname: Padmawar
  fullname: Padmawar, Prashant
– sequence: 4
  givenname: Christopher
  surname: Morrison
  fullname: Morrison, Christopher
– sequence: 5
  givenname: A.S.
  surname: Verkman
  fullname: Verkman, A.S.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18824527$$D View this record in MEDLINE/PubMed
BookMark eNp1kU2P0zAYhCO0iP2AK0fkC9xS_CaxnVyQoLBQaYFDi8TNcp03jcGxg52U7W_gT-NVlxUg7cmW_MyMPHOenTjvMMueAl0AFNXLwdsF0HpBGWVcPMjOgBWQUwA4yc4oLXheN-zraXYe4zdKoWI1fZSdQl0XFSvEWfZr0xs_9uhQq7D11werJiTreRwDxugD8R1ZHrQ1mnyatUU_mRYjeWui9nsM2BLjiCLrQVmbf_QW9WyTXgdER95Yr79HsvHXxuUr18468Ss3YZyMU5Zc2tm0ZI2Jnox3j7OHnbIRn9yeF9mXy3eb5Yf86vP71fL1Va4rLqa8EAwKJpoaFZYllKpBDi3nZcMVFSUUAoALpmpAvYVGdajaRpS87HgnhGrKi-zV0XectwO2Gt0UlJVjMIMKB-mVkf--ONPLnd_LgtepZpYMXtwaBP9jTr-RQ-oDrVUO_RwlT_G0BJ7AZ38n3UX86T8B1RHQwccYsJPaTOqmjBRsrAQqb2aWaeZ0r-Vx5iRb_Ce7c75P8Pwo6M2u_2kCyrFXYVDaW787SMEkSCirxNVHDlP_e4NBRm3Qpd2SRk-y9ea-iN82y80e
CitedBy_id crossref_primary_10_1021_jm200505e
crossref_primary_10_1681_ASN_2015010057
crossref_primary_10_1038_ki_2009_438
crossref_primary_10_1681_ASN_2013040398
crossref_primary_10_1124_mol_109_061051
crossref_primary_10_1016_j_coph_2013_08_005
crossref_primary_10_1053_j_ackd_2010_01_006
crossref_primary_10_1016_j_cellsig_2020_109649
crossref_primary_10_1016_j_niox_2017_09_007
crossref_primary_10_1002_jcp_28094
crossref_primary_10_1097_MOG_0b013e3283358a45
crossref_primary_10_1093_ckj_sfy103
crossref_primary_10_1089_adt_2010_0313
crossref_primary_10_4155_fmc_13_42
Cites_doi 10.1085/jgp.200409059
10.1124/mol.107.034496
10.1161/01.RES.0000256354.95791.f1
10.1172/JCI200318326
10.1016/S0140-6736(03)15328-7
10.1023/A:1014231722696
10.1016/j.cell.2007.09.037
10.1172/JCI0216112
10.1016/j.semnephrol.2008.03.003
10.1128/IAI.74.3.1505-1515.2006
10.1146/annurev.physiol.68.040504.094707
10.1007/s00441-006-0226-0
10.1007/s00706-003-0161-7
10.1124/mol.63.5.1094
10.1053/j.gastro.2003.11.005
10.1016/S0188-4409(99)00078-8
10.1681/ASN.2007070828
10.1152/ajpcell.1993.265.4.C859
10.1073/pnas.86.15.6007
10.1074/jbc.M212723200
10.1021/jo00141a028
10.4161/cc.5.6.2582
10.1161/01.RES.0000087541.15600.2B
10.2174/1568008054064805
10.1124/pr.58.3.5
10.1016/j.tips.2005.02.003
10.3109/00313029209068884
ContentType Journal Article
Copyright 2006 American Society for Pharmacology and Experimental Therapeutics
Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics
Copyright_xml – notice: 2006 American Society for Pharmacology and Experimental Therapeutics
– notice: Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1124/mol.108.050567
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE



Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0111
EndPage 142
ExternalDocumentID PMC2685055
18824527
10_1124_mol_108_050567
75_1_134
S0026895X24146597
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL073856
– fundername: NHLBI NIH HHS
  grantid: HL59198
– fundername: NIBIB NIH HHS
  grantid: EB00415
– fundername: NIDDK NIH HHS
  grantid: DK35124
– fundername: NIDDK NIH HHS
  grantid: P30 DK072517
– fundername: NHLBI NIH HHS
  grantid: HL73856
– fundername: NEI NIH HHS
  grantid: EY13574
– fundername: NIDDK NIH HHS
  grantid: DK72517
GroupedDBID ---
-~X
.55
.GJ
0R~
123
18M
2WC
34G
39C
4.4
53G
5RE
5VS
AAJMC
AALRI
AAXUO
ABCQX
ABJNI
ABSQV
ACGFO
ACGFS
ADBBV
ADCOW
AENEX
AERNN
AFFNX
AFHIN
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AYCSE
BAWUL
BTFSW
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HH5
HZ~
IH2
INIJC
K-O
KQ8
L7B
LSO
M41
MVM
N9A
O9-
OK1
P2P
R.V
R0Z
RHF
RHI
ROL
RPT
TR2
UQL
VXZ
W8F
WOQ
X7M
XOL
YBU
YHG
ZGI
ZXP
-
0R
55
AALRV
AAPBV
ABFLS
ABSGY
ABZEH
ADACO
ADBIT
DL
FH7
HZ
O0-
X
ZA5
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c467t-275125798eae3313a9e61d66396a07312711675a81ecb19afead97363f6f77a93
ISSN 0026-895X
1521-0111
IngestDate Thu Aug 21 18:11:10 EDT 2025
Fri Jul 11 11:35:04 EDT 2025
Thu Apr 03 07:05:10 EDT 2025
Tue Jul 01 05:34:16 EDT 2025
Thu Apr 24 23:07:18 EDT 2025
Tue Jan 05 21:17:00 EST 2021
Sat Feb 22 15:41:36 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c467t-275125798eae3313a9e61d66396a07312711675a81ecb19afead97363f6f77a93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
Address correspondence to: Dr. Alan S. Verkman, 1246 Health Sciences East Tower, Box 0521, University of California, San Francisco, San Francisco, CA 94143-0521. E-mail: alan.verkman@ucsf.edu
This work was supported by grants DK72517, DK35124, HL59198, EY13574, EB00415, and HL73856 from the National Institutes of Health, and Research Development Program (R613) and Drug Discovery grants from the Cystic Fibrosis Foundation.
ABBREVIATIONS: PDE, phosphodiesterase; CFTR, cystic fibrosis transmembrane conductance regulator; V2R, vasopressin-V2 receptor; dDAVP, desmopressin; CTX, cholera toxin; STa, Escherichia coli heat-stable toxin; CPT, chlorophenylthio; IBMX, 3-isobutyl-1-methylxanthine; FRT, Fisher rat thyroid; YFP, yellow fluorescent protein; MDCK, Madin-Darby canine kidney; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; DMSO, dimethyl sulfoxide; ES-MS, electrospray mass spectroscopy; MRP, multidrug resistance protein; PDE, phosphodiesterase; CNT, cyclic nucleotide.
OpenAccessLink http://doi.org/10.1124/mol.108.050567
PMID 18824527
PQID 66750316
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2685055
proquest_miscellaneous_66750316
pubmed_primary_18824527
crossref_citationtrail_10_1124_mol_108_050567
crossref_primary_10_1124_mol_108_050567
highwire_pharmacology_75_1_134
elsevier_sciencedirect_doi_10_1124_mol_108_050567
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-01-01
PublicationDateYYYYMMDD 2009-01-01
PublicationDate_xml – month: 01
  year: 2009
  text: 2009-01-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmacology
PublicationTitleAlternate Mol Pharmacol
PublicationYear 2009
Publisher Elsevier Inc
American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: Elsevier Inc
– name: American Society for Pharmacology and Experimental Therapeutics
References Vaandrager (REF23) 2002; 230
Rybalkin, Yan, Bornfeldt, Beavo (REF17) 2003; 93
Miklos, Hetenyi, Sohar, Stajer (REF11) 2004; 135
Ma, Thiagarajah, Yang, Sonawane, Folli, Galietta, Verkman (REF8) 2002; 110
Murthy (REF14) 2006; 68
Sack, Sack, Nair, Siddique (REF18) 2004; 363
Barkla, Whitehead, Hayward (REF1) 1992; 24
Muanprasat, Sonawane, Salinas, Taddei, Galietta, Verkman (REF12) 2004; 124
Murakami, Kamiya, Yanagita, Mori (REF13) 1999; 30
Omori, Kotera (REF15) 2007; 100
Thiagarajah, Verkman (REF21) 2005; 26
Li, Krishnamurthy, Penmatsa, Marrs, Wang, Zaccolo, Jalink, Li, Nelson, Schuetz (REF7) 2007; 131
Thiagarajah, Broadbent, Hsieh, Verkman (REF20) 2004; 126
Crane, Choudhari, Naeher, Duffey (REF5) 2006; 74
Barrett (REF2) 1993; 265
Field (REF6) 2003; 111
Torres (REF22) 2008; 28
Yang, Sonawane, Zhao, Somlo, Verkman (REF26) 2008; 19
Reid, Wielinga, Zelcer, De Haas, Van Deemter, Wijnholds, Balzarini, Borst (REF16) 2003; 63
Wielinga, van der Heijden, Reid, Beijnen, Wijnholds, Borst (REF25) 2003; 278
Yangthara, Mills, Chatsudthipong, Tradtrantip, Verkman (REF27) 2007; 72
van Staveren, Detours, Dumont, Maenhaut (REF24) 2006; 5
Meyer, Guizzardi, Rodighiero, Manfredi, Saino, Sironi, Garavaglia, Bazzini, Bottà, Portincasa (REF10) 2005; 5
Bender, Beavo (REF3) 2006; 58
Mangoo-Karim, Uchic, Lechene, Grantham (REF9) 1989; 86
Sweeney, Avner (REF19) 2006; 326
Canonne, Belanger, Lemay (REF4) 1982; 47
Rybalkin (10.1124/mol.108.050567_REF17) 2003; 93
Sack (10.1124/mol.108.050567_REF18) 2004; 363
Murakami (10.1124/mol.108.050567_REF13) 1999; 30
Ma (10.1124/mol.108.050567_REF8) 2002; 110
Vaandrager (10.1124/mol.108.050567_REF23) 2002; 230
Omori (10.1124/mol.108.050567_REF15) 2007; 100
Reid (10.1124/mol.108.050567_REF16) 2003; 63
Torres (10.1124/mol.108.050567_REF22) 2008; 28
Yang (10.1124/mol.108.050567_REF26) 2008; 19
Canonne (10.1124/mol.108.050567_REF4) 1982; 47
Murthy (10.1124/mol.108.050567_REF14) 2006; 68
Li (10.1124/mol.108.050567_REF7) 2007; 131
Wielinga (10.1124/mol.108.050567_REF25) 2003; 278
Thiagarajah (10.1124/mol.108.050567_REF21) 2005; 26
Crane (10.1124/mol.108.050567_REF5) 2006; 74
Bender (10.1124/mol.108.050567_REF3) 2006; 58
van Staveren (10.1124/mol.108.050567_REF24) 2006; 5
Miklos (10.1124/mol.108.050567_REF11) 2004; 135
Mangoo-Karim (10.1124/mol.108.050567_REF9) 1989; 86
Field (10.1124/mol.108.050567_REF6) 2003; 111
Yangthara (10.1124/mol.108.050567_REF27) 2007; 72
Thiagarajah (10.1124/mol.108.050567_REF20) 2004; 126
Barkla (10.1124/mol.108.050567_REF1) 1992; 24
Sweeney (10.1124/mol.108.050567_REF19) 2006; 326
Meyer (10.1124/mol.108.050567_REF10) 2005; 5
Barrett (10.1124/mol.108.050567_REF2) 1993; 265
Muanprasat (10.1124/mol.108.050567_REF12) 2004; 124
References_xml – volume: 30
  start-page: 514
  year: 1999
  end-page: 521
  ident: REF13
  article-title: Gs alpha mutations in hyperfunctioning thyroid adenomas
  publication-title: Arch Med Res
– volume: 93
  start-page: 280
  year: 2003
  end-page: 291
  ident: REF17
  article-title: Cyclic GMP phosphodiesterase and regulation of smooth muscle function
  publication-title: Circ Res
– volume: 63
  start-page: 1094
  year: 2003
  end-page: 1103
  ident: REF16
  article-title: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance protein-MRP4 and MRP5
  publication-title: Mol Pharmacol
– volume: 111
  start-page: 931
  year: 2003
  end-page: 943
  ident: REF6
  article-title: Intestinal ion transport and the pathophysiology of diarrhea
  publication-title: J Clin Invest
– volume: 47
  start-page: 3953
  year: 1982
  end-page: 3959
  ident: REF4
  article-title: Novel synthesis of five- and six-membered spiro g-lactones in rigid bicyclic systems
  publication-title: J Org Chem
– volume: 126
  start-page: 511
  year: 2004
  end-page: 519
  ident: REF20
  article-title: Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor
  publication-title: Gastroenterology
– volume: 26
  start-page: 172
  year: 2005
  end-page: 175
  ident: REF21
  article-title: New drug targets for cholera therapy
  publication-title: Trends Pharmacol Sci
– volume: 5
  start-page: 571
  year: 2006
  end-page: 572
  ident: REF24
  article-title: Negative feedbacks in normal cell growth and their suppression in tumorigenesis
  publication-title: Cell Cycle
– volume: 135
  start-page: 839
  year: 2004
  end-page: 847
  ident: REF11
  article-title: Preparation and structure of di-exo-condensed norbornane heterocycles
  publication-title: Monatsh Chem
– volume: 28
  start-page: 306
  year: 2008
  end-page: 317
  ident: REF22
  article-title: Vasopressin antagonists in polycystic kidney disease
  publication-title: Semin Nephrol
– volume: 265
  start-page: C859
  year: 1993
  end-page: C868
  ident: REF2
  article-title: Positive and negative regulation of chloride secretion in T84 cells
  publication-title: Am J Physiol
– volume: 86
  start-page: 6007
  year: 1989
  end-page: 6011
  ident: REF9
  article-title: Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP
  publication-title: Proc Natl Acad Sci U S A
– volume: 74
  start-page: 1505
  year: 2006
  end-page: 1515
  ident: REF5
  article-title: Mutual enhancement of virulence by enterotoxigenic and enteropathogenic
  publication-title: Infect Immun
– volume: 58
  start-page: 488
  year: 2006
  end-page: 520
  ident: REF3
  article-title: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
  publication-title: Pharmacol Rev
– volume: 110
  start-page: 1651
  year: 2002
  end-page: 1658
  ident: REF8
  article-title: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion
  publication-title: J Clin Invest
– volume: 131
  start-page: 940
  year: 2007
  end-page: 951
  ident: REF7
  article-title: Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia
  publication-title: Cell
– volume: 68
  start-page: 345
  year: 2006
  end-page: 374
  ident: REF14
  article-title: Signaling for contraction and relaxation in smooth muscle of the gut
  publication-title: Annu Rev Physiol
– volume: 100
  start-page: 309
  year: 2007
  end-page: 327
  ident: REF15
  article-title: Overview of PDEs and their regulation
  publication-title: Circ Res
– volume: 24
  start-page: 296
  year: 1992
  end-page: 301
  ident: REF1
  article-title: Effects of cholera toxin on human colon carcinoma cell lines
  publication-title: Pathology
– volume: 326
  start-page: 671
  year: 2006
  end-page: 685
  ident: REF19
  article-title: Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD)
  publication-title: Cell Tissue Res
– volume: 278
  start-page: 17664
  year: 2003
  end-page: 17671
  ident: REF25
  article-title: Charcaterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells
  publication-title: J Biol Chem
– volume: 230
  start-page: 73
  year: 2002
  end-page: 83
  ident: REF23
  article-title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C
  publication-title: Mol Cell Biochem
– volume: 72
  start-page: 86
  year: 2007
  end-page: 94
  ident: REF27
  article-title: Small-molecule vasopressin-2 receptor antagonist identified by a G-protein coupled receptor “pathway” screen
  publication-title: Mol Pharmacol
– volume: 124
  start-page: 125
  year: 2004
  end-page: 137
  ident: REF12
  article-title: Discovery of glycine hydrazide pore occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy
  publication-title: J Gen Physiol
– volume: 363
  start-page: 223
  year: 2004
  end-page: 233
  ident: REF18
  article-title: Cholera
  publication-title: Lancet
– volume: 19
  start-page: 1300
  year: 2008
  end-page: 1310
  ident: REF26
  article-title: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease
  publication-title: J Am Soc Nephrol
– volume: 5
  start-page: 143
  year: 2005
  end-page: 151
  ident: REF10
  article-title: Ion transport across the gall bladder epithelium
  publication-title: Curr Drug Targets Immune Endocr Metabol Disord
– volume: 124
  start-page: 125
  year: 2004
  ident: 10.1124/mol.108.050567_REF12
  article-title: Discovery of glycine hydrazide pore occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy
  publication-title: J Gen Physiol
  doi: 10.1085/jgp.200409059
– volume: 72
  start-page: 86
  year: 2007
  ident: 10.1124/mol.108.050567_REF27
  article-title: Small-molecule vasopressin-2 receptor antagonist identified by a G-protein coupled receptor “pathway” screen
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.107.034496
– volume: 100
  start-page: 309
  year: 2007
  ident: 10.1124/mol.108.050567_REF15
  article-title: Overview of PDEs and their regulation
  publication-title: Circ Res
  doi: 10.1161/01.RES.0000256354.95791.f1
– volume: 111
  start-page: 931
  year: 2003
  ident: 10.1124/mol.108.050567_REF6
  article-title: Intestinal ion transport and the pathophysiology of diarrhea
  publication-title: J Clin Invest
  doi: 10.1172/JCI200318326
– volume: 363
  start-page: 223
  year: 2004
  ident: 10.1124/mol.108.050567_REF18
  article-title: Cholera
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)15328-7
– volume: 230
  start-page: 73
  year: 2002
  ident: 10.1124/mol.108.050567_REF23
  article-title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C
  publication-title: Mol Cell Biochem
  doi: 10.1023/A:1014231722696
– volume: 131
  start-page: 940
  year: 2007
  ident: 10.1124/mol.108.050567_REF7
  article-title: Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia
  publication-title: Cell
  doi: 10.1016/j.cell.2007.09.037
– volume: 110
  start-page: 1651
  year: 2002
  ident: 10.1124/mol.108.050567_REF8
  article-title: Thiazolidinone CFTR inhibitor identified by high throughput screening blocks cholera toxin-induced intestinal fluid secretion
  publication-title: J Clin Invest
  doi: 10.1172/JCI0216112
– volume: 28
  start-page: 306
  year: 2008
  ident: 10.1124/mol.108.050567_REF22
  article-title: Vasopressin antagonists in polycystic kidney disease
  publication-title: Semin Nephrol
  doi: 10.1016/j.semnephrol.2008.03.003
– volume: 74
  start-page: 1505
  year: 2006
  ident: 10.1124/mol.108.050567_REF5
  article-title: Mutual enhancement of virulence by enterotoxigenic and enteropathogenic Escherichia coli
  publication-title: Infect Immun
  doi: 10.1128/IAI.74.3.1505-1515.2006
– volume: 68
  start-page: 345
  year: 2006
  ident: 10.1124/mol.108.050567_REF14
  article-title: Signaling for contraction and relaxation in smooth muscle of the gut
  publication-title: Annu Rev Physiol
  doi: 10.1146/annurev.physiol.68.040504.094707
– volume: 326
  start-page: 671
  year: 2006
  ident: 10.1124/mol.108.050567_REF19
  article-title: Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD)
  publication-title: Cell Tissue Res
  doi: 10.1007/s00441-006-0226-0
– volume: 135
  start-page: 839
  year: 2004
  ident: 10.1124/mol.108.050567_REF11
  article-title: Preparation and structure of di-exo-condensed norbornane heterocycles
  publication-title: Monatsh Chem
  doi: 10.1007/s00706-003-0161-7
– volume: 63
  start-page: 1094
  year: 2003
  ident: 10.1124/mol.108.050567_REF16
  article-title: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance protein-MRP4 and MRP5
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.63.5.1094
– volume: 126
  start-page: 511
  year: 2004
  ident: 10.1124/mol.108.050567_REF20
  article-title: Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2003.11.005
– volume: 30
  start-page: 514
  year: 1999
  ident: 10.1124/mol.108.050567_REF13
  article-title: Gs alpha mutations in hyperfunctioning thyroid adenomas
  publication-title: Arch Med Res
  doi: 10.1016/S0188-4409(99)00078-8
– volume: 19
  start-page: 1300
  year: 2008
  ident: 10.1124/mol.108.050567_REF26
  article-title: Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2007070828
– volume: 265
  start-page: C859
  year: 1993
  ident: 10.1124/mol.108.050567_REF2
  article-title: Positive and negative regulation of chloride secretion in T84 cells
  publication-title: Am J Physiol
  doi: 10.1152/ajpcell.1993.265.4.C859
– volume: 86
  start-page: 6007
  year: 1989
  ident: 10.1124/mol.108.050567_REF9
  article-title: Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.86.15.6007
– volume: 278
  start-page: 17664
  year: 2003
  ident: 10.1124/mol.108.050567_REF25
  article-title: Charcaterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M212723200
– volume: 47
  start-page: 3953
  year: 1982
  ident: 10.1124/mol.108.050567_REF4
  article-title: Novel synthesis of five- and six-membered spiro g-lactones in rigid bicyclic systems
  publication-title: J Org Chem
  doi: 10.1021/jo00141a028
– volume: 5
  start-page: 571
  year: 2006
  ident: 10.1124/mol.108.050567_REF24
  article-title: Negative feedbacks in normal cell growth and their suppression in tumorigenesis
  publication-title: Cell Cycle
  doi: 10.4161/cc.5.6.2582
– volume: 93
  start-page: 280
  year: 2003
  ident: 10.1124/mol.108.050567_REF17
  article-title: Cyclic GMP phosphodiesterase and regulation of smooth muscle function
  publication-title: Circ Res
  doi: 10.1161/01.RES.0000087541.15600.2B
– volume: 5
  start-page: 143
  year: 2005
  ident: 10.1124/mol.108.050567_REF10
  article-title: Ion transport across the gall bladder epithelium
  publication-title: Curr Drug Targets Immune Endocr Metabol Disord
  doi: 10.2174/1568008054064805
– volume: 58
  start-page: 488
  year: 2006
  ident: 10.1124/mol.108.050567_REF3
  article-title: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.58.3.5
– volume: 26
  start-page: 172
  year: 2005
  ident: 10.1124/mol.108.050567_REF21
  article-title: New drug targets for cholera therapy
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2005.02.003
– volume: 24
  start-page: 296
  year: 1992
  ident: 10.1124/mol.108.050567_REF1
  article-title: Effects of cholera toxin on human colon carcinoma cell lines
  publication-title: Pathology
  doi: 10.3109/00313029209068884
SSID ssj0014580
Score 2.039561
Snippet We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the...
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the...
We carried out a "pathway" screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the...
We carried out a “pathway” screen of 50,000 small molecules to identify novel modulators of cAMP signaling. One class of compounds, the...
SourceID pubmedcentral
proquest
pubmed
crossref
highwire
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 134
SubjectTerms Animals
Cell Line
Cells, Cultured
CHO Cells
Cholera Toxin - antagonists & inhibitors
Cricetinae
Cricetulus
Cyclic AMP - metabolism
Cyclic GMP - metabolism
Cystic Fibrosis Transmembrane Conductance Regulator - metabolism
Disease Models, Animal
Dogs
Inorganic Chemicals - chemical synthesis
Inorganic Chemicals - chemistry
Inorganic Chemicals - metabolism
Intestinal Secretions - metabolism
Kidney - cytology
Mice
Mice, Inbred Strains
Molecular Structure
Nucleotides, Cyclic - analysis
Nucleotides, Cyclic - antagonists & inhibitors
Polycystic Kidney Diseases - drug therapy
Rats
Rats, Inbred F344
Stereoisomerism
Structure-Activity Relationship
Thyroid Gland - cytology
Thyroid Gland - metabolism
Transfection
Title Thiophenecarboxylate Suppressor of Cyclic Nucleotides Discovered in a Small-Molecule Screen Blocks Toxin-Induced Intestinal Fluid Secretion
URI https://dx.doi.org/10.1124/mol.108.050567
http://molpharm.aspetjournals.org/content/75/1/134.abstract
https://www.ncbi.nlm.nih.gov/pubmed/18824527
https://www.proquest.com/docview/66750316
https://pubmed.ncbi.nlm.nih.gov/PMC2685055
Volume 75
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadchh_QeOgyyL1-RGhjQt3oQyeVJ8txHBatTaomESt_gb_Aj-WcONfRistLVDmO6_Z89rnk-DuEvLZ9BWozsIzIjhiGbhxjHPqmIcB7jtjYMUOJh5PPzr3TC-fT3J0PBj87WUtFHhzJ71vPlfyPVKEN5IqnZP9Bss2g0ACfQb5wBQnD9S9lHCMtQKKkWAfp9WYBhuMoK1Zlcmtaxv_lRiKNdYK0xWkehyrDdzISEzcV0i6NxChbisXCWOo6ufC8xFQczGiXV0j_cB0nBjjuhSz758jKgRZstCjicJSh1dnItq4MVZfcHa1aYuwmdA_aMcxBQ-ZxWRpvUlwtRaIafH0RydccWaRL5BXr7r2pCJfim04Jn65FdinarJ2zdF2WU7zBmNCLarBOVKPaiC1sqDZitaWt2r113ZUeSvVWbOog6e8qwnJArvCnYnrlERby0_VA-lzc55_5ycVkwmfH89ktctsCJwTrY3ycNwlEpuOWdfmaWVWUoDD-2_7ou0yehpF6m3dzM0m3Y_XM7pG7lbtC32vs3ScDlTwgB1Mt1s0hnbXH97JDekCnHYE_JD-2AZS2AKVpRDVAaQegtAUojRMqaB-gVAOUaoDSHkBpC1BaApQ2AH1ELk6OZx9Ojar6hyFBeeeG5YMt6vpsrISybdMWTHlmCAYy8wToJdPy8RWiK8amkoHJRAR7IvNtz468yPcFsx-TvSRN1FNCmftOWIqB5WpFjjcWTDgscGTAvMAKhFJDYtQC4rKixscKLQteusiWw-EnIpUu1wIdkjdN_5UmhdnZ06zlzSuTVpuqHOC485n9Ghi8u0y573KTA6yH5FUNFw7KAN_wwVpMi4x7HqYlmN6QPNHgaacHnrTjWjC434NV0wFp5vt3kviypJu3vDHMy332x299Tu60S_kF2cvXhXoJJnse7Jcr5xcsOfo3
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thiophenecarboxylate+suppressor+of+cyclic+nucleotides+discovered+in+a+small-molecule+screen+blocks+toxin-induced+intestinal+fluid+secretion&rft.jtitle=Molecular+pharmacology&rft.au=Tradtrantip%2C+Lukmanee&rft.au=Yangthara%2C+Buranee&rft.au=Padmawar%2C+Prashant&rft.au=Morrison%2C+Christopher&rft.date=2009-01-01&rft.issn=1521-0111&rft.eissn=1521-0111&rft.volume=75&rft.issue=1&rft.spage=134&rft_id=info:doi/10.1124%2Fmol.108.050567&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon